vVardis Sets Terms for U.S. IPO of Up to $229 Million

vVardis has set terms for a proposed U.S. initial public offering that could raise up to $228.6 million in gross primary proceeds.

In an amended Form F-1 filed November 6, the Swiss dental-products company said it plans to offer 9,523,810 new Class A ordinary shares at an expected price of $21 to $24 per share. Its shares have been approved for listing on the New York Stock Exchange under the symbol VVVV, subject to completion of the offering.

The transaction has not yet priced or closed. The filing is a proposed offering, not a completed capital raise.

Underwriters also have an option to buy up to 1,428,571 additional shares from selling shareholders. vVardis would not receive those secondary-sale proceeds.

The dental business behind the IPO

vVardis develops Curodont, a peptide-based product line for early-stage cavities. Its principal U.S. product, Curodont Repair Fluoride Plus, is applied in a dental office and is intended to support enamel remineralization without drilling or injections.

The filing shows rapid U.S. commercial adoption since the product's January 2024 launch:

• vVardis estimates that Curodont products had been applied to more than 3.5 million teeth by June 30, 2026.
• Its flagship products had been sold to more than 20,000 of approximately 110,000 U.S. general dental practices.
• Preliminary net revenue for the nine months ended September 30, 2026 is expected to be $47.7 million to $49.2 million, up 114% to 121% from a year earlier.
• Curodont Repair Fluoride Plus unit volume increased 112% to approximately 214,000 units during that nine-month period.
• The company reported 11,158 recurring buying practices in September, up 74%, while average units per practice increased by more than 20%.

Those figures make the offering relevant beyond the company itself. Public dental markets are dominated by diversified manufacturers and distributors. A single-product growth company reaching the NYSE would give investors a more direct way to value preventive dental innovation and practice-level adoption.

The contrast with Avized's recent analysis of Dentsply Sirona's dental-segment declines is especially useful. Large portfolios are currently contending with soft equipment, imaging, implant and orthodontic demand. vVardis is presenting a narrower growth story built around a new treatment category.

Growth has not produced profitability

The revenue trajectory is strong, but the company remains unprofitable.

vVardis expects a preliminary net loss of $39.7 million to $41.3 million for the first nine months of 2026, compared with a $40.7 million loss a year earlier. Adjusted EBITDA is expected to remain negative at approximately $9.2 million to $9.4 million.

That gap matters. The IPO is not simply financing greater distribution of an already mature cash-generating product. Investors are being asked to fund continued commercial expansion while judging whether rapid adoption can eventually absorb operating and financing costs.

For dental operators, the filing offers a reminder that product adoption and vendor durability are different questions. A product can spread quickly across practices while the company behind it is still building the economics required for long-term independence.

This is the same distinction emphasized in Avized's analysis of dental's next value-creation cycle: growth is more persuasive when it produces repeatable operating performance, not only customer counts or distribution reach.

Distribution concentration is a central risk

The U.S. growth story depends heavily on one channel.

vVardis grants Henry Schein exclusive U.S. distribution rights for specified Curodont products, provided the distributor meets customer thresholds. The agreement uses fixed pricing through January 1, 2027, after which vVardis may reset prices with six months' notice. Henry Schein also receives the best available price offered to similarly situated distributors, excluding certain direct DSO sales.

The filing says distributors are not required to purchase minimum quantities. A significant reduction or delay in purchases could therefore affect revenue, while exclusivity limits vVardis' ability to diversify the U.S. channel.

That arrangement may accelerate reach across independent practices, but it also concentrates commercial execution. Investors will need to distinguish true end-practice consumption from distributor purchasing patterns and inventory movement.

For DSOs, the filing also signals that direct enterprise relationships may remain strategically important even within an exclusive distribution model. Scale increasingly affects how dental organizations buy, standardize and deploy products—a theme quantified in Avized's analysis of the Dental Spend Index and DSO supply-cost gap.

Why this IPO matters to the dental market

If completed, the offering would be one of the most visible dental capital-markets events of 2026.

It would test three propositions:

1. Whether public investors will pay for category creation. vVardis is not positioning Curodont as another restorative material. It is presenting a different intervention point for early caries.
2. Whether practice penetration converts into recurring demand. Initial stocking matters less than repeat purchasing and increased utilization inside adopting practices.
3. Whether dental distribution can support venture-style growth. Exclusive distribution offers reach, but it can also create pricing, concentration and inventory risk.

The filing is also unusually transparent about adoption. Practice counts, recurring buyers, unit volumes and average units per practice provide a more useful commercialization picture than a single revenue-growth percentage.

What to watch next

Final pricing and completion. The $21–$24 range is preliminary. The deal could price outside the range, change size, be delayed or be withdrawn.

Net proceeds. Gross proceeds would range from approximately $200 million to $228.6 million before underwriting discounts and offering expenses. Secondary over-allotment shares would not fund the company.

Recurring practice demand. Continued growth in repeat buyers and units per practice would be stronger evidence than additional one-time practice placements.

Losses and cash use. Revenue growth has not yet produced profitability. Investors should watch operating expense, interest costs and the path toward positive cash generation.

Distributor dependence. U.S. results remain closely tied to Henry Schein's purchasing, inventory and commercial execution.

Clinical and payer adoption. Wider use may depend on how practices integrate the treatment into diagnosis, patient communication, coding and reimbursement workflows—not only on product availability.

The larger market signal is that preventive dental innovation is reaching the public-capital stage. The offering's outcome will help show whether investors view that shift as a durable new category or an early adoption curve that still needs stronger economic proof.

Primary source

• vVardis Holding AG — Amendment No. 1 to Form F-1, filed November 6, 2026

All offering terms, adoption figures and financial estimates are attributed to vVardis' SEC filing. The IPO remains proposed and subject to change. Avized's market implications are independent editorial analysis.